(2015. november 1.) „A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update”. Clinical Gastroenterology and Hepatology13 (12), 2071–87.e16. o. DOI:10.1016/j.cgh.2015.07.007. PMID26188135.
(2012. július 1.) „Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals”. The Cochrane Database of Systematic Reviews7 (7), CD007189. o. DOI:10.1002/14651858.CD007189.pub3. PMID22786505.
(2015. június 1.) „Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use”. Infectious Diseases and Therapy4 (2), 145–57. o. DOI:10.1007/s40121-015-0070-1. PMID26032649.
(2013. június 12.) „Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012”. PLOS ONE8 (6), e66223. o. DOI:10.1371/journal.pone.0066223. PMID23776637.
(2016. november 1.) „Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen”. Expert Review of Clinical Pharmacology9 (11), 1493–1503. o. DOI:10.1080/17512433.2016.1221760. PMID27498720.
(2009. július 1.) „The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards”. Journal of Chromatography B877 (20–21), 1907–14. o. DOI:10.1016/j.jchromb.2009.05.029. PMID19493710.
(2006) „Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment”. Clinical Pharmacokinetics45 (11), 1115–24. o. DOI:10.2165/00003088-200645110-00005. PMID17048975.
Tenofovir Disoproxil Fumarate. The American Society of Health-System Pharmacists. [2016. november 30-i dátummal az eredetiből archiválva]. (Hozzáférés: 2016. november 29.)
(2015. november 1.) „A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update”. Clinical Gastroenterology and Hepatology13 (12), 2071–87.e16. o. DOI:10.1016/j.cgh.2015.07.007. PMID26188135.
(2012. július 1.) „Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals”. The Cochrane Database of Systematic Reviews7 (7), CD007189. o. DOI:10.1002/14651858.CD007189.pub3. PMID22786505.
(2015. június 1.) „Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use”. Infectious Diseases and Therapy4 (2), 145–57. o. DOI:10.1007/s40121-015-0070-1. PMID26032649.
(2013. június 12.) „Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, ANRS CO3 Aquitaine cohort, France, 2004-2012”. PLOS ONE8 (6), e66223. o. DOI:10.1371/journal.pone.0066223. PMID23776637.
(2016. november 1.) „Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen”. Expert Review of Clinical Pharmacology9 (11), 1493–1503. o. DOI:10.1080/17512433.2016.1221760. PMID27498720.
(2009. július 1.) „The simultaneous assay of tenofovir and emtricitabine in plasma using LC/MS/MS and isotopically labeled internal standards”. Journal of Chromatography B877 (20–21), 1907–14. o. DOI:10.1016/j.jchromb.2009.05.029. PMID19493710.
(2006) „Pharmacokinetics and dosing recommendations of tenofovir disoproxil fumarate in hepatic or renal impairment”. Clinical Pharmacokinetics45 (11), 1115–24. o. DOI:10.2165/00003088-200645110-00005. PMID17048975.
pubchem.ncbi.nlm.nih.gov
Pubchem: Tenofovir disoproxil (angol nyelven). pubchem.ncbi.nlm.nih.gov. (Hozzáférés: 2018. április 17.)
Tenofovir Disoproxil Fumarate. The American Society of Health-System Pharmacists. [2016. november 30-i dátummal az eredetiből archiválva]. (Hozzáférés: 2016. november 29.)